Reps. John Dingell and Bart Stupak aren’t only interested inLipitor advertising. In the wake of the release of Enhance trial data, the duosent letters to Merck and Schering-Plough vowing an investigation and makingclear that DTC ads for the drug would be a major focus.
“Given the frequency of Vytorinadvertisements, it concerns us that a study showing that Vytorin provides noincreased benefit was not issued for nearly two years while (DTC ads) werecarried on the airwaves,” they wrote. “This situation raises concerns that thedrug companies and their advertisement agencies profited at the significantexpense of patients’ health.”
From the February 01, 2008 Issue of MM+M - Medical Marketing and Media
